First-year treatment costs among new initiators of topical prostaglandin analogs
Jordana K Schmier1, David W Covert2, Alan L Robin3,41Exponent Inc., Alexandria, VA, USA; 2Health Economics, Alcon Research Ltd., Fort Worth, TX, USA; 3Department of Ophthalmology, University of Maryland, Baltimore, MD, USA; 4Wilmer Eye Institute, Bloomberg School of Public Health, Johns Hopkins Univ...
Guardado en:
Autores principales: | Jordana K Schmier, David W Covert, Alan L Robin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/62eb13ec8ab144a9ba10979da407cdd2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
por: Jordana K Schmier, et al.
Publicado: (2010) -
Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2010) -
Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
por: Schmier JK, et al.
Publicado: (2014) -
Characteristics of respondents with glaucoma and dry eye in a national panel survey
por: Jordana K Schmier, et al.
Publicado: (2009) -
Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
por: Michael B Horsley, et al.
Publicado: (2009)